James Moore, MD
Neurology · Faribault, MNNPI 1730264037
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.6% of the total across 56 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Harmony Biosciences LLC at 39.4% of the total. Reporting peaked in 2024 at $1,002 and has fallen 59.4% since, to $407 in 2025.
Across 56 payments — averaging $28.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Harmony Biosciences LLC$619
- Sanofi$377
- Axsome Therapeutics, Inc.$341
- Jazz Pharmaceuticals Inc.$175
- Philips North America LLC$28
- Fisher & Paykel Healthcare Inc$17
- plus $17 from 1 others
What the payments were for
- Food & beverage$1,48795%
- Education$855%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Harmony Biosciences LLC | 25 | $619 |
| Sanofi | 5 | $377 |
| Axsome Therapeutics, Inc. | 14 | $341 |
| Jazz Pharmaceuticals Inc. | 8 | $175 |
| Philips North America LLC | 2 | $28 |
| Fisher & Paykel Healthcare Inc | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
How this compares
$1,572 in reported general payments places this provider in the 75th percentile of 434 neurology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Carbidopa-LevodopaCarbidopa/Levodopa | 32 | $1,542 |
| Memantine Hcl | 13 | $1,065 |
| Levetiracetam | 11 | $944 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 33 | $473 |
| Donepezil Hcl | 14 | $362 |
| Pregabalin | 11 | $340 |
| Lamotrigine | 26 | $236 |
| Topiramate | 14 | $134 |
| Clonazepam | 31 | $36 |
| Zolpidem Tartrate | 12 | $33 |
Paid to pharmacies, not to this prescriber.
Other neurology in Faribault
- Jeffery AllenMinneapolis$1.1M
- Jonathan CalkwoodGolden Valley$493K
- Alejandro RabinsteinRochester$305K
- Patricia PenovichSaint Paul$304K
- Sean PittockRochester$231K
- Irfan AltafullahGolden Valley$203K
- Jessica StulcGolden Valley$199K
- Akram DastagirGolden Valley$174K
- Jessica HeiringGolden Valley$149K
- Shelly Larson-PetersBlaine$143K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.